RankingsPricing
  1. US-listed companies
  2. OCULAR THERAPEUTIX, INC
  3. Financials
  4. Stock-based compensation

OCULAR THERAPEUTIX, INCOCUL

Market cap
$2.3B
P/E ratio
SummaryFinancials
Period EndStock-based compensation (Million USD)YoY (%)
Dec 31, 202433+85.74%
Dec 31, 202318+5.08%
Dec 31, 202217+13.27%
Dec 31, 202115+98.87%
Dec 31, 20208-14.02%
Dec 31, 20199+17.05%
Dec 31, 20187+2.21%
Dec 31, 20177+22.92%
Dec 31, 20166+28.36%
Dec 31, 20155+75.49%
Dec 31, 20143

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)